Leal Therapeutics (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- October 31, 2024
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $45,000,000
Company Info
- Founding Year
- 2021
- Traction
- The company plans to submit IND applications for LTX-002 and LTX-001 by the end of 2024 and commence first-in-human clinical trials in early 2025.
- Founders
- Asa Abeliovich
- Company Description
- Leal Therapeutics is a biotechnology company dedicated to developing novel precision medicines for patients with high-need central nervous system disorders. The company focuses on antisense oligonucleotide (ASO) and small molecule therapeutics.
- Market
- Central Nervous System Disorders
- Location
- Worcester, Massachusetts, USA
- Coinvestors
- Chugai Venture Fund, Alexandria Venture Investments, OrbiMed, Euclidean Capital, PhiFund